<DOC>
	<DOCNO>NCT00928421</DOCNO>
	<brief_summary>To determine effect safety Varisolve速 0.125 % [ 0.2 % ]</brief_summary>
	<brief_title>An Open-label , Single-dose Pilot Study Evaluate Varisolve速 ( Polidocanol Endovenous Microfoam ( PEM ) ) 0.125 % 0.2 % Varicose Veins</brief_title>
	<detailed_description>In patient SFJ incompetence due reflux Great Saphenous Vein ( GSV ) major accessory vein , venous disease manifest symptom visible varicosity : use duplex ultrasonography , evaluate efficacy Varisolve速 0.125 % [ 0.2 % ] assess elimination SFJ reflux and/or occlusion treat vein</detailed_description>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Polidocanol</mesh_term>
	<criteria>1 . Male female ; age consent 75 year 2 . Baseline VEINESSym Questionnaire score less 75 point 3 . Superficial venous disease manifest symptom visible varicosity 4 . Varicose vein clinical classification CEAP 2 5 5 . Incompetence SFJ ( reflux &gt; 0.5 second duplex ultrasonography ) associate incompetence great saphenous vein ( GSV ) major accessory vein 6 . Ability comprehend sign inform consent document complete study questionnaire English 1 . Incompetence small saphenous vein ( SSV ) 2 . Ultrasonographic evidence current previous deep vein thrombosis , occlusion incompetence 3 . Leg obesity impair ability access vein treat and/or follow postprocedural compression recommendation . 4 . Peripheral arterial disease leg treat contraindicate postprocedural compression . 5 . Reduced mobility ( inability maintain brisk walk unaided minimum 5 minute per hour per day ) . 6 . Planned prolonged automobile , bus , air travel within 4 week follow treatment , unless patient walk least 5 consecutive minute every hour travel . 7 . History pulmonary embolism stroke . 8 . Major surgery , prolong hospitalization pregnancy within 3 month screen . 9 . Current anticoagulation therapy ( within 7 day enrollment ) . 10 . Participation clinical study involve investigational pharmaceutical product device within 3 month prior screen . 11 . Previous treatment study previous Varisolve速 study . 12 . Major coexist disease ( e.g . malignancy ; pulmonary disease ; renal hepatic insufficiency ; serious skin disease/condition may compromise ability patient comply compression protocol , etc . ) clinically significant laboratory abnormality . 13 . Known allergic response polidocanol , severe multiple allergic reaction . 14 . Women childbearing potential use effective contraception least one month prior study enrollment and/or unwilling continue birth control last study visit . 15 . Pregnant lactating woman . 16 . Current alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Varicose Veins</keyword>
</DOC>